Elixira: The Business Model – How Cancer Prevention Is 11× More Profitable Than Cancer Treatment
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | inglés |
| Publicado: |
Zenodo
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866902126912864256 |
|---|---|
| author | Fries, Tess |
| author_facet | Fries, Tess |
| contents | <p dir="ltr">Invented and founded by Tess Fries in 2025, Elixira is a breakthrough patent-pending AI-guided nanomedicine platform designed for autonomous, lifelong cancer prevention. Its feasibility has been independently documented by a leading Contract Research Organization (CRO), all underlying technologies are supported by existing scientific literature.</p> <p dir="ltr">This white paper presents an economic analysis suggesting that preventing cancer with Elixira may be significantly more profitable than treating it, and how it increases profit for pharmaceutical companies, healthcare systems and stakeholders—while being completely free of charge for the patient. </p> <p dir="ltr">Unlike today’s treatment models, which generate revenue only after illness and serve only the sick, Elixira applies to the entire population, protecting health for life before disease strikes. Beyond cancer, its platform can be expanded to prevent other major diseases.<br>To date, I am not aware of any published business model demonstrating that prevention may be more profitable than treatment. Elixira may represent a potential shift in this paradigm, suggesting a highly profitable and ethically aligned preventive model—the first preventive medicine model that transcends treatment. This paper presents an analysis indicating that prevention may be more profitable than treatment, and that the one thing the world truly cannot afford—is to not implement cancer prevention globally in healthcare. </p> <p>For licensing inquiries: <a href="mailto:licensing@elixira.tech">licensing@elixira.tech</a></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17765133 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Elixira: The Business Model – How Cancer Prevention Is 11× More Profitable Than Cancer Treatment Fries, Tess Elixira Nanoism Tess Fries Preventive Medicine Nanomedicine Nanotechnology Business Model Cancer Prevention Disease Prevention Lifelong Prevention AI-Guided Nanobot Pharmaceutical Revenues Healthcare Economics Sustainable Healthcare Artificial Intelligence AI Global Health Economics Cancer Burden Public Health Investment <p dir="ltr">Invented and founded by Tess Fries in 2025, Elixira is a breakthrough patent-pending AI-guided nanomedicine platform designed for autonomous, lifelong cancer prevention. Its feasibility has been independently documented by a leading Contract Research Organization (CRO), all underlying technologies are supported by existing scientific literature.</p> <p dir="ltr">This white paper presents an economic analysis suggesting that preventing cancer with Elixira may be significantly more profitable than treating it, and how it increases profit for pharmaceutical companies, healthcare systems and stakeholders—while being completely free of charge for the patient. </p> <p dir="ltr">Unlike today’s treatment models, which generate revenue only after illness and serve only the sick, Elixira applies to the entire population, protecting health for life before disease strikes. Beyond cancer, its platform can be expanded to prevent other major diseases.<br>To date, I am not aware of any published business model demonstrating that prevention may be more profitable than treatment. Elixira may represent a potential shift in this paradigm, suggesting a highly profitable and ethically aligned preventive model—the first preventive medicine model that transcends treatment. This paper presents an analysis indicating that prevention may be more profitable than treatment, and that the one thing the world truly cannot afford—is to not implement cancer prevention globally in healthcare. </p> <p>For licensing inquiries: <a href="mailto:licensing@elixira.tech">licensing@elixira.tech</a></p> |
| title | Elixira: The Business Model – How Cancer Prevention Is 11× More Profitable Than Cancer Treatment |
| topic | Elixira Nanoism Tess Fries Preventive Medicine Nanomedicine Nanotechnology Business Model Cancer Prevention Disease Prevention Lifelong Prevention AI-Guided Nanobot Pharmaceutical Revenues Healthcare Economics Sustainable Healthcare Artificial Intelligence AI Global Health Economics Cancer Burden Public Health Investment |
| url | https://doi.org/10.5281/zenodo.17765133 |